EU approves Relistor for Opioid-Induced Constipation In Advanced Illness Patients « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
July 2008

M T W T F S S

« Jun Aug »

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30 31

EU approves Relistor for Opioid-Induced Constipation In Advanced Illness Patients

Posted on July 7, 2008 by crimsoncanary

Wyeth and Progenics have received marketing approval for Relistor (methylnaltrexone bromide) subcutaneous injection in the EU for the treatment of opioid-induced constipation in advanced illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient.

Filed under: gpcr | Tagged: antagonist, Methylnaltrexone, Opioid mu, progenics, Relistor, Wyeth

« Procter & Gamble Ends Collaboration on ATI-7505 Almirall and Forest complete Phase III trials of Aclidinium in COPD »

Leave a Reply